Introduction
============

The effect of combined oral contraceptives (COCs) on female sexuality has long been a matter of discussion ([@bib1]). According to a systematic review in the field, however, mainly based on observational studies, approximately 15% of COC users report decreased sexual desire ([@bib2]). At present, despite the bulk of literature, only two randomised placebo-controlled trials have investigated the causal influence of COCs on sexual function ([@bib3], [@bib4]). Both of these studies evaluated a pill introduced in the 1970s, containing ethinyl oestradiol (EE) and levonorgestrel, and the findings pointed to a COC-induced reduction in sexual desire ([@bib4], [@bib5]). However, since the 1970s, attempts have been made to reduce side effects from combined oral contraceptives by introducing less androgenic progestogens and by also substituting the synthetic oestrogen ethinyl with oestradiol. At present, placebo-controlled studies on sexual function in women using oestradiol-containing COCs are lacking.

Receptors for sex steroid hormones have widespread expression in genital tissues and the brain, and sex hormones are thought to play a role in female sexuality ([@bib6]). While no clear-cut relationship between androgen levels and sexual desire has been established in COC users ([@bib2], [@bib4]), many still believe that the COC-induced decrease in bioavailable testosterone may negatively affect sexual function ([@bib2], [@bib7], [@bib8]). Hormone measurement in hair is a new method that allows non-invasive sampling of the unbound testosterone fraction ([@bib9], [@bib10]). Further, the method enables retrospective evaluation of hormone levels across time, making it suitable for longitudinal assessment in COC users ([@bib11], [@bib12]).

Because of the lack of knowledge regarding the influence of oestradiol-based COCs on female sexual function, this randomised controlled trial (RCT) aimed to compare changes in sexual function between women treated with an oestradiol-based COC or placebo. A secondary aim was to investigate associations between sexual function and testosterone in serum and hair.

Subjects and methods
====================

Participants
------------

This investigator-initiated RCT was conducted at the Departments of Obstetrics and Gynaecology at Uppsala University Hospital, the Karolinska University Hospital, Södersjukhuset Stockholm, Linköping University Hospital, Örebro University Hospital, Umeå University Hospital and Närhälsan Maternity Health Care Centre, Gothenburg. The study investigates several aspects of COC use, including mood side effects ([@bib13]).

Enrolment took place between September 2013 and May 2015. Healthy, non-obese (BMI \<30 kg/m^2^) women aged 18--35 years were recruited by advertisements in local newspapers, on local notice boards and students' websites. The women had to confirm they would use barrier contraceptives or copper intrauterine device (IUD) while participating. No study-specific exclusion criteria were used. As in clinical routine, women with prior history of venous thromboembolism, known predisposition for venous thromboembolism, systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg, known dyslipidaemia, migraine with focal symptoms, inflammatory bowel disease, first-degree relatives with cardiovascular disease at a young age, previous cancer, liver disease and previous pancreatitis were excluded.

Notably, current psychiatric disorders or use of psychotropic drugs were not reasons for exclusion. Ongoing primary depressive or anxiety disorders were assessed by use of the Mini International Neuropsychiatric Interview 6.0.0 ([@bib14]). Women were categorised as suffering from any mood disorder if they fulfilled criteria for major or minor depressive disorder or dysthymia. Similarly, women who fulfilled diagnostic criteria for panic disorder, generalised anxiety disorder, social phobia or obsessive-compulsive disorder were classified as having an anxiety disorder.

All women gave written informed consent prior to inclusion. The study was approved by the regional Ethical Review Board, EPN 2013/161 Uppsala, and the Medical Products Agency in Sweden and was pre-registered: EUDRA-CT 2013-000925-30.

Study design
------------

The study was a double-blind, randomised, parallel-group clinical trial during which the participants were treated with a COC (1.5 mg oestradiol and 2.5 mg nomegestrol acetate) or placebo during three 24/4 treatment cycles. During the screening visit blood and hair samples were collected and women filled out the McCoy Female Sexuality Questionnaire (MFSQ) ([@bib15]). Following the screening visit, at least one menstrual cycle (baseline cycle) passed before randomisation and start of treatment. During the baseline cycle, no hormonal contraceptive use was allowed. Women switching from another hormonal contraceptive (HC) filled out the MFSQ and donated blood and hair samples at the randomisation visit, that is, following at least 1-month washout.

The National Corporation of Swedish Pharmacies in Stockholm prepared identical capsules containing either COC or placebo, and performed the packaging and randomisation (computerised random-number generator in blocks of four). At randomisation, the container with the lowest available randomization number was distributed to the participant. During the study, the participants and study personnel were not informed about which treatment the patient received, and randomisation codes were kept at the Uppsala University Hospital Pharmacy until completion of the study.

Following randomisation, women started taking the COC or placebo capsules once daily on the first day of the next-coming menstruation and continued treatment for 24 days, followed by four pill-free days. The study lasted three treatment cycles. After two treatment cycles, the participants met with the study coordinator to receive treatment for the third and final cycle. The fourth and final visit was made during the last week of treatment. Any adverse events or changes in concomitant medication were actively asked for and registered at each visit. Compliance was checked by counting remaining capsules at study completion. Pregnancy tests were taken once at baseline and before the start of each treatment cycle.

The primary outcome was change in the MFSQ scores ([@bib15]). The MFSQ was chosen as it originally was designed to measure aspects of female sexuality likely to be affected by changing hormone levels ([@bib14]). The questionnaire assesses sexual function during the past 4 weeks and consists of 19 questions, 18 answered using a 7-point Likert scale, where 1 represents negative answers such as 'not at all enjoyable' or 'never', whereas 7 represents positive answers such as 'very enjoyable' or 'every time', Supplementary Table 1 (see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article). One question assessed intercourse frequency, reported as number of intercourses per day, week or month.

The MFSQ questions are categorised into six domains; Sexual Interest, Satisfaction with Frequency of Sexual Activity, Vaginal Lubrication, Orgasm, Partner and Attractiveness, Supplementary Table 1. According to McCoy, the domain Satisfaction with Frequency of Sexual Activity is a summary score of the items Satisfaction with Frequency of Sexual Activity, Decreased Satisfaction due to Partner's Interest and Frequency of Intercourse. As many women reported that they did not have a steady partner at baseline, the question on frequency was analysed separately. The items for Vaginal Lubrication and Orgasm were only answered by women who had engaged in sexual intercourse during the past 4 weeks. A clinically relevant deterioration in sexual desire and vaginal lubrication was defined as at least 30% decrease in the score from baseline to the last visit.

Depressive mood was captured at the screening visit and the final treatment visit, by use of the self-rated version of the Montgomery-Åsberg Depression Rating Scale (MADRS-S) ([@bib16]). The MADRS-S scores reflect depressive symptoms during the past 3 days on a scale ranging from 0 to 54.

Hormonal analyses
-----------------

Blood and hair samples from participants were taken at the screening or randomisation visit and at the final visit. A lock of hair was cut as close as possible to the scalp, with the proximal end marked. The most proximal 3 cm hair segment was finely cut with scissors and samples of about 10 mg of hair were prepared.

Testosterone in hair was measured using a competitive radioimmunoassay in speed-vaced methanol extracts of homogenised hair ([@bib10]). The radio ligand was ^125^I-labelled testosterone-3-CMO-histamine and rabbit antiserum (T4276, Sigma Aldrich) was used which cross-reacts 23.0, 1.5, 0.2 and 1.7% with 5α-dihydrotestosterone, 17α-epitestosterone, dehydroepiandrosterone and androstenedione, respec­tively. The calibrator was testosterone (Sigma Aldrich T5411) verified with a European pharmacopoeia reference standard (EDQM, Strasbourg, France). All hair samples were analysed in the same assay, the intra-assay coefficient of variation (CV)% for testosterone in hair was 9.6% at 10 pg/mL, 3.0% at 45 pg/mL and 2.9% at 90 pg/mL.

Testosterone and sex hormone binding globulin (SHBG) in serum were measured with chemiluminescence ([@bib10]). The analyses were performed with a Cobas EE (Roche Diagnostics). Total CV for testosterone was 5% at 2.2 nmol/L and 3% at 23 nmol/L. No samples were below detection level. Total CV for SHBG was 3% at 38 nmol/L and 3% at 109 nmol/L. All blood analyses were performed at the Department of Clinical Chemistry, Uppsala University hospital, which is an accredited laboratory. Free androgen index was calculated as (testosterone/SHBG) ×100.

Statistics
----------

The power analysis was based on data from Graham and colleagues who used a five-point scale for assessment of sexual desire ([@bib7]). Assuming that the SD was twice the size (0.6 scale steps) of the reported difference between the COC and placebo (0.3 scale steps), this study would reach 80% power to detect a significant difference (*P* \< 0.05) between treatments, with 80 subjects in each treatment arm completing the trial.

Demographic data were compared between groups by Student's *t*-test or chi-square tests. Delta (Δ)-scores were calculated for the MFSQ domains as difference between the final treatment cycle and baseline, meaning that negative Δ-scores indicate worsening and positive Δ-scores indicate improvement. Baseline and delta scores were compared between treatment groups by Mann--Whitney *U* test. Ordinal regression analyses on the MFSQ items sexual interest and lubrication were performed, adjusted for change in self-rated depression scores (ΔMADRS-s). Correlations between serum testosterone, hair testosterone, free androgen index and MFSQ domains obtained during the final treatment cycle were performed by use of Spearman's rank correlation. In addition, correlation analyses were performed between Δ-scores in the sexual function variables and Δ-scores in testosterone variables. The SPSS 22.0 statistical package was used (IBM), and *P* values less than 0.05 were considered statistically significant.

Results
=======

Study participants
------------------

Two-hundred twenty-four women were screened for the study. Of these, 202 women were randomised; 102 to the COC and 100 women to placebo ([Fig. 1](#fig1){ref-type="fig"}). Eighteen women allocated to COC and six women allocated to placebo dropped out at various stages of the study, with an overall drop-out rate of 11.9%. Withdrawal of consent was the most common reason for drop-out, however, five women in the COC group discontinued due to side effects, and one woman in the placebo group became pregnant. Among the women who discontinued due to side effects, one did so because of a combination of sexual side effects and mood side effects, whereas two complained of mood side effects, one developed bleeding problems and one reported on worsening of migraine. In the end, 84 women in the COC group and 94 women in the placebo group continued with the allocated intervention and completed the trial. Compliance was very good; none of the women had more than 1 or 2 capsules remaining at the end of the study. Figure 1Flowchart of the study population.

Eighty-one women randomised to COC and 90 women randomised to placebo answered the MFSQ both at the baseline and at the final assessment. Fifty-seven (67.9%) women randomised to COC and 59 (63.4%) women randomised to placebo correctly guessed their treatment upon completion of the study. Adverse events are presented in Supplementary Table 2. Thirteen COC users (12.7%) spontaneously reported sexual side effects, whereas the corresponding number among placebo users was three (3.0%), *P* = 0.01 (Supplementary Table 2).

No baseline differences in demographic and clinical variables or baseline MFSQ scores were noted between the two treatment groups ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Table 1Demographic and clinical variables in the study population (*n* = 202).Clinical variablesCombined oral contraceptive (*n* = 102)Placebo (*n* = 100)*P*Age (years)23.8 ± 4.224.8 ± 4.20.097Married/partner, *n* (%)61 (59.8)49 (49.5)0.158University education, *n* (%)78 (76.5)75 (76.5)0.992BMI (kg/m^2^)22.3 ± 2.622.5 ± 2.50.532Smokers, *n* (%)7 (6.9)8 (8.2)0.727Previous hormonal contraceptive use, *n* (%)84 (82.4)82 (82.0)0.947Duration of previous hormonal contraceptive use (years)4.8 ± 3.54.8 ± 3.30.945Intercourse last four weeks75 (74.3)74 (77.9)0.551Dysmenorrhoea, *n* (%)3 (2.9)8 (8.0)0.113Endometriosis, *n* (%)1 (1.0)0 (0.0)1.00PCOS, *n* (%)2 (2.0)0 (0.0)0.498Any mood disorder, *n* (%)9 (8.8)5 (5.0)0.285Any anxiety disorder, *n* (%)7 (6.9)8 (8.0)0.758Current use of psychotropic drugs9 (8.8)7 (7.0)0.631 Serotonin reuptake inhibitors8 (7.8)5 (5.0)0.410 Other2 (2.0)2 (2.0)1.000[^2][^3] Table 2Sexual function scores on the McCoy Female Sexuality Questionnaire at baseline.Maximum score*N*Combined oral contraceptive*N*Placebo*P*Sexual interest2810119.0 (16.0--21.0)9619.0 (16.0--23.0)0.704Satisfaction sexual activity1410010.0 (7.3--11.0)9510.0 (7.0--11.0)0.989Vaginal lubrication^a^217516.0 (13.0--18.0)7416.0 (13.0--18.3)0.368Orgasm^a^287519.0 (14.0--22.0)7419.0 (13.8--22.5)0.932Partner218519.0 (16.0--21.0)7619.0 (16.0--20.0)0.437Attractiveness141019.0 (6.5--10.5)959.0 (7.0--11.0)0.297Frequency, intercourse/week961 (0.0--2.0)951 (0.25--2.50)0.435Total score10188.0 (54.5--100.5)9690.5 (62.7--100.0)0.720[^4][^5]

Sexual function during treatment
--------------------------------

Sexual function delta scores are displayed in [Table 3](#tbl3){ref-type="table"}. Women randomised to the COC reported a significant decrease in sexual interest at the completion of the trial compared with women randomised to placebo (*P* = 0.019). This finding remained following adjustment for self-rated change in depressive symptoms; *B* = −0.80 ± 0.30, Wald = 7.08, *P* = 0.008. However, the proportion of women with clinically relevant reduction in sexual desire scores did not differ between treatments (COC 18 (22.2%) vs placebo 16 (17.8%), *P* = 0.47). Table 3Delta sexual function scores on the McCoy Female Sexuality Questionnaire during the final treatment cycle.*n*Combined oral contraceptive*N*Placebo*P*Sexual interest81−2.0 (−5.0 to 0.5)90−1.0 (−3.0 to 2.0)0.019Satisfaction sexual activity800.0 (−2.0 to 0.0)890.0 (−1.0 to 1.0)0.060Vaginal lubrication^a^57−2.0 (−3.0 to 1.0)580.0 (−1.0 to 2.0)0.005Orgasm^a^57−1.0 (−4.0 to 1.0)580.0 (−2.3 to 2.0)0.147Partner670.0 (−2.0 to 0.0)660.0 (−2.0 to 1.3)0.398Attractiveness800.0 (−2.0 to 1.0)900.0 (−2.0 to 1.0)0.488Frequency, intercourse/week710.0 (−1.0 to 0.25)860.0 (−0.75 to 0.25)0.800Total score81−5 (−17.0 to 2.1)90−2.0 (−13.0 to 10.0)0.086[^6][^7]

Among the women who had engaged in sexual intercourse both at baseline and during treatment, COC users reported a decrease in vaginal lubrication compared with women in the placebo group (*P* = 0.005) ([Table 3](#tbl3){ref-type="table"}). This finding did not remain following adjustment for change in self-rated depressive symptoms, *B* = −0.22 ± 0.32, Wald = 0.48, *P* = 0.487. Further, the proportion of women with clinically relevant reduction in lubrication scores did not differ between treatments (COC 11 (14.7%) vs placebo 12 (15.6%), *P* = 0.87).

No differences in total score, satisfaction with sexual activity, frequency of sexual activity, satisfaction with partner, orgasm or attractiveness were noted between the treatment groups ([Table 3](#tbl3){ref-type="table"}).

Testosterone
------------

On average, serum testosterone levels decreased, SHBG levels increased and free androgen index decreased during treatment with the COC ([Table 4](#tbl4){ref-type="table"}). However, for most women testosterone levels remained stable throughout the trial ([Fig. 2](#fig2){ref-type="fig"}). In addition, levels of testosterone in hair were unaltered after three cycles of COC or placebo ([Table 4](#tbl4){ref-type="table"}). No correlation between testosterone variables and sexual function was noted at the end of the study, data not shown. However, when including both women on active treatment and placebo, we found weak positive correlations between change in testosterone levels and free androgen levels and change in sexual desire and satisfaction with sexual activities ([Table 5](#tbl5){ref-type="table"}). These associations were driven by a sub-group of women with greater change in testosterone levels, predominantly in the placebo group ([Fig. 2](#fig2){ref-type="fig"}) (COC users; testosterone and sexual interest rho = 0.07, *P* = 0.564, satisfaction with sexual activities rho = 0.01, *P* = 0.915, placebo users; testosterone and sexual interest rho = 0.27, *P* = 0.012, satisfaction with sexual activities rho = 0.36, *P* = 0.001). Figure 2Spearman rank correlations between change in total testosterone and change in sexual function scores in each treatment group. The associations were mainly driven by the placebo users (testosterone and sexual interest rho = 0.27, *P* = 0.012, satisfaction with sexual activities rho = 0.36, *P* = 0.001), whereas no association between testosterone and sexual function scores were noted in the COC users (testosterone and sexual interest rho = 0.07, *P* = 0.564, satisfaction with sexual activities rho = 0.01, *P* = 0.915). Table 4Testosterone, sex hormone-binding globulin, free androgen index and hair testosterone at baseline and during treatment with a combined oral contraceptive or placebo.Baseline*P*Treatment*P*^a^COC (*n* = 97)Placebo (*n* = 99)COC (*n* = 76)Placebo (*n* = 89)Testosterone (nmol/L)1.54 (1.22--2.10)1.53 (1.25--2.00)NS1.37 (1.04--1.77)1.67 (1.27--2.15)0.002SHBG72 (47--104)75 (54--99)NS103 (74--129)62 (44--81)0.000Free androgen index2.40 (1.39--4.04)2.11 (1.39-- 3.28)NS1.44 (0.95--2.08)2.87 (1.80--4.57)0.000(*n* = 90)(*n* = 87)(*n* = 75)(*n* = 78)Hair testosterone (pg/mg)1.33 (1.02--1.92)1.28 (0.95--1.69)NS1.26 (1.02--1.74)1.41 (1.00--1.81)NS[^8][^9][^10] Table 5Spearman rank correlation coefficients between serum testosterone, sex hormone-binding globulin, free androgen index, and hair testosterone and sexual function scores at the end of the study.Testosterone (rho)SHBG (rho)Free androgen index (rho)Hair testosterone (rho)Sexual interest0.229^b^−0.1480.231^b^−0.129Satisfaction sexual activity0.252^b^−0.1190.272^b^0.023Vaginal lubrication0.154−0.830.1460.147Orgasm0.173−0.330.0260.198Partner0.1610.0920.0370.135Attractiveness0.145−0.1060.203^a^−0.032Frequency, intercourse/week0.192^a^−0.0070.1280.060[^11]

Discussion
==========

Main findings
-------------

Our study demonstrates that use of an oral contraceptive containing 1.5 mg of oestradiol and 2.5 mg of nomegestrolacetate is associated with a small decrease in sexual interest, even following adjustment for change in depressive symptoms throughout the study course. However, no difference in the proportion of women who reported clinically relevant deterioration in sexual interest was noted between treatments. In a sub-group of women, the change in testosterone levels may also influence sexual desire.

Strengths and limitations
-------------------------

Our study is the first randomised placebo-controlled trial on sexual function using an oestradiol-containing COC. Oestradiol-based COCs have less impact on SHBG levels than EE-containing pills, consequently less impact on bioavailable testosterone levels and have been proven beneficial in women with COC-induced sexual dysfunction ([@bib17], [@bib18]). This is also the first study evaluating the effects of COCs on long-term bioavailable testosterone levels by measurement of hair testosterone. Strengths of the study include the fact that we used no study-specific exclusion criteria, which should increase the generalizability of the results. For instance, studies that have only included women not using HCs for at least 6 months prior to inclusion, are at increased risk of selectively recruiting women with previous negative experiences of hormonal contraception ([@bib3]). The study design, with six geographically dispersed centres including patients, should also increase generalizability. Further, the drop-out rate was low and compliance with treatment was high.

However, the study is not without limitations. First, blinding might have been jeopardised since bleeding irregularities are common during COC use. Indeed, about two thirds of the women in both the COC and in the placebo groups correctly guessed which treatment they had received. Secondly, the duration of study treatment was only three treatment cycles, and long-term effects on sexual function were not assessed. However, more prolonged studies may lead to selection bias and a 'healthy survivor effect', which would limit the interpretations that can be drawn. In line with this, it may be speculated that the higher discontinuation rate among the women allocated to active treatment have diminished the differences regarding sexual function found between the groups. In support of this, spontaneously reported sexual side effects were more common in the active treatment group, and at least one of the women who dropped out did so because of sexual side effects. Finally, our study population was young with a median age of 24 years, and 54% reported being in a stable relationship upon inclusion. Given the fairly young cohort, it is possible that relationship status fluctuated during the study, in turn affecting responses to the MFSQ. Hopefully, however, randomisation made the proportion of changed relationship similar in the two groups.

Interpretation
--------------

The relation between oral contraceptive use and sexual function has been extensively discussed, but causality has been difficult to prove. Results from the present study are in line with two recently published studies, one placebo-controlled ([@bib4]) and one randomised without placebo ([@bib5]). Together, these studies add to the evidence that COC may negatively affect sexual interest in women. However, the differences in median sexual interest change scores between treatments was small, and the proportion of women with clinically relevant impairment did not differ between treatments. Overall, these findings suggest that an oestradiol-based COC may impair sexual desire at the statistical level, but with unclear clinical relevance.

It has been suggested that COC-induced effects on sexual desire may be mediated by COC-induced depressed mood ([@bib3], [@bib19]) or change in quality of life ([@bib20], [@bib21]). A previous publication from the present study ([@bib13]) reported that the COC was associated with increased reporting of anxiety, irritability and mood swings and suggested that the progestogen component could contribute to these effects. We found no evidence of a mediation effect by COC-induced depressed mood on sexual desire. Instead, the relationship between HC use and sexual desire was strengthened when change in self-rated depressive symptoms was adjusted for in the regression analysis.

Weak positive correlations between change in serum testosterone and free androgen index and sexual desire and satisfaction with sexual activity were noted, in line with some previous findings in the field ([@bib2]). As most women had relatively stable levels of total and free testosterone throughout the trial, these associations seem driven by a sub-group of women with greater change in total and free testosterone, predominantly in the placebo group. Testosterone levels in hair remained unchanged throughout the trial. However, the incorporation and stability of steroid hormones in scalp hair may be affected by yet unknown variables, which warrant further methodological research on the clinical utility of hair testosterone analysis.

Conclusion
----------

Our study suggests that a combined oral contraceptive with 1.5 mg oestradiol and 2.5 mg nomegestrolacetate is associated with a small, but not clinically relevant, decrease in sexual desire. Further studies are needed to explore which HCs would be most beneficial for women in terms of sexual function, preferably head-to-head comparisons between different preparations.
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